AAV development for cell and gene therapy in 2023 is being impacted by manufacturing and regulation challenges, however advancing technologies offer opportunity, according to leaders in the field.
As proven by recent regulatory approvals sweeping the cell and gene therapy industry, particularly within Europe and the US, these pioneering treatments have demonstrated great capacity in helping to resolve hard-to-treat diseases.
Comments are closed.